Panel Discussion: Oral solid dosage forms: Trends and opportunities

Panelists in this video:
+ Vinod Arora, Principal Advisor, Institute of Good Manufacturing Practices India (IGMPI) (Moderator)
+ Dr Kavita Inamdar, CTO, Indoco Remedies
+ Dr Krishnakant Gandhi, MD, Solinova Life Sciences
+ Ravi Kochhar, Head – R&D, Beximco Pharmaceuticals, Bangladesh

Key Highlights:
● Biologics is growing at a CAGR of 35% plus and by 2028, it will be a $119 billion market: Vinod Arora, Principal Advisor, Institute of Good Manufacturing Practices India (IGMPI)

● Fixed-dose combinations have clinical advantage like better safety profile and business advantage like better pricing: Dr Kavita Inamdar, CTO, Indoco Remedies

● Continuous manufacturing offers flexibility, robustness, and reduction in manpower and energy, but there are also challenges associated with mindset, regulation and technology balance: Dr Krishnakanth Gandhi, MD, Solinova Life Sciences

● Dosage forms like mini tabs and micro tabs are the way forward. As we move along patient-centric dosage forms and ease of dosing, this trend will go on and we have to build upon it: Ravi Kochhar, Head-R&D, Beximco Pharmaceuticals, Bangladesh